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A Method for Evaluating the Platelet Surface Response by Using
Electron Microscopyt
Jeanne M. Riddle, PhD*

Our method for evaluating the surface response of any
given platelet population, which has evolved over the past
two decades, provides a measure of both the adhesive and
cohesive qualities of platelets. General morphologic features of the adherent, whole platelets can be assessed by
transmission electron microscopy, and the results are reproducible when serial samples are collected on normal
subjects and patient groups. With this technique, different
metabolites and drugs can be combined with platelet pop-

ulations that are either normoresponsive or hyperactive to
determine if these substances trigger or inhibit the platelet
response. To date, the results from in vitro studies have
paralleled
in vivo findings during clinical trials. The
method appears suitable for assessing the degree of surface
response for any platelet population, determining the in
vitro action of a variety of substances on the platelet
response, and for monitoring the antiplatelet capacity of
established as well as experimental therapeutic agents.

Introduction

(3,5). We were able to identify four classical stages of
surface activation during a platelet differential count that
evaluated surface response for 100 successive platelets.
These four w e r e : r o u n d , d e n d r i t i c , intermediate, and
spread types (6). Since 1958, we have revised our method
by i n t r o d u c i n g c o m m e r c i a l l y available, nonwettable
equipment, by changing the anticoagulant from heparin to
3.8% sodium citrate, and by combining the intermediate
and spread types in order to simplify the differential count
(7). Our current method is as follows:

Early investigators demonstrated that platelets removed
from the interior of blood vessels and placed in an anticoagulated, in vitro system exhibited structural alterations.
If the anticoagulated sample of blood was exposed to a
foreign surface such as the exterior of a glass microscope
slide or support films used in electron microscopy (collodion and Formvar), an ordered sequence of shape changes
took place (1-3). Rebuck's appreciation ofthe significance
of these structural changes led us in 1958 to devise a
method to assess the surface response o f a platelet population in normal subjects and disease states. We chose the
transmission electron microscope over the light microscope because of its greater resolving power and increased
range of magnification.

Venipuncture procedure

* Department of Internal Medicine, Division of Rheumatology, Henry Ford
Hospital

Peripheral blood is obtained by venipuncture (Fig. 1) using
a siliconized Butterfly infusion set with an attached 21
gauge needle (Abbott Hospitals, Inc, North Chicago, 111).
Individual samples are collected into sterile, disposable
plastic syringes (Becton, Dickinson, and Co, Rutherford,
NJ). First, a 2 ml whole blood sample is withdrawn and
discarded to eliminate any procoagulant substances that
might have been introduced during venipuncture. A second syringe containing 1 ml of 3.8% sodium citrate is
attached immediately to the tubing, and 9 ml of whole
blood is withdrawn into the anticoagulant, which is mixed
briefly with the whole blood. Additional samples can be
obtained if the effect of a specific metabolite or drug is to
be evaluated.

Address reprint requests to Dr. Riddle, Director, Rheumatology Research
Laboratory, Henry Ford H o s p i t a l , 2 7 9 9 W G r a n d B l v d , D e t r o i t , M l
48202

Ex vivo method of platelet collection

* ' See pp. 255-67 of this issue for a reprint of "Contributions of electron
microscopy to the study of platelets" from the 1960 Henry Ford
Hospital Medical Bulletin.

The anticoagulated blood specimen is transferred immediately to a 6 oz polyethylene, square bottle with a wide
mouth (Nagle Co, Rocherter, NY), and a nonfrosted micro-

Materials and Methods
Our original method was first published in 1959 (4)** and
modified a technique previously used by Braunsteiner
i Supported in part by grants from the Michigan Chapter of the Arthritis
Foundation and from Merck, Sharp and Dohme.
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scope slide covered with a thin film of Formvar (1% Formvar dissolved in ethylene d i c h l o r i d e ) is introduced
horizontally (Fig. 2). The system either remains at room
temperature or is placed in a 37°C incubator. A stopwatch
is started, and the blood mixture remains in contact with
the Formvar film for exactly eight minutes. During incubation, blood platelets and other activated cellular elements
attach to the surface of the Formvar lilm. Afterwards, the
microscope slide is removed from the bottle, drained
briefly, and rinsed in Tyrode's solution previously warmed
to room temperature. Rinsing continues until erythrocytes
are no longer grossly visible on the film surface. The slide is
immersed in either cacodylate buffered 3% glutaraldehyde
(8) or 1% buffered osmium fixative (9) for 15 rninutes at
room temperature to stabilize the structure of the adherent
cellular elements. After fixation, the slide is rinsed in
several changes of distilled water to remove the buffer salts.
The preparation is then air dried (Fig. 2).

Fig. 3

tion adhering to the surface is surveyed with a phase
microscope, and stainless steel, 200 mesh specimen grids
(Ernest R Ful lam, Schenectady, NY) are placed over representative areas so that their convex surfaces contact the
Formvar film. The final mounting of the preparation is
outlined in Fig. 3. After mounting, platelet populations are
viewed with a transmission electron microscope operated
at 50 KV.

Next, the edges ofthe slide are scraped with a No. 22 BardParker blade to free the Formvar film. The platelet popula-
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Based on their degree of surface activation, three distinct
types of platelets are observed in these preparations. The
round type is compact, has a smooth contour, and is
uniformly electron-dense. The dendritic type has a compact, electron-dense central area and several extruding
pseudopodia (7). The spread type contains transitional
forms that exhibit varying amounts of hyalomeric fusion
and spreading as well as obvious centralization of their
cytoplasmic organelles (27). Platelet aggregates are observed also. Sometimes these are composed of a single
platelet type; sometimes they contain an admixture of
types and exhibit peripheral cytoplasmic spreading.

Platelet Response by Electron Microscopy

Platelet differential count
Our differential platelet count of 100 successive platelet
types measures the capacity of platelets to: 1) adhere to a
foreign surface; and 2) cohere and form aggregates. Values
for round and dendritic types, indicative of minimal surface
activation, are combined, and a single value for spread
types, including the transitional intermediate type, is recorded. Round and dendritic platelets consistently dominate the differential counts of asymptomatic subjects, with
a mean value of 88% ± 7%. On the average, the spread
type comprises only 12% ± 7% ofthe differential count in
the control group. The number of platelet aggregates per
differential count is noted also. The aggregating tendency
of platelet populations from the control group varies over a
wider range, with an average of 68 ± 50 aggregates per
100 single platelets counted.

A

The reproducibility of our method was established by
performing serial differential counts on platelet samples
from several subjects at various time intervals. The consistency of our data demonstrate that our method can be
applied to assess the activation quality and aggregating
capacity of platelet populations from a single subject during follow-up studies in clinical trials.

B

#

C

D
Fig. 4

A. Abortive pseudopodial formation on dendritic type platelets in untreated pernicious anemia (X5,900); B. Serrated border on platelets from
patients w i t h ITP ( X 1 5 , 4 0 0 ) ; C. P r e v e n t i o n o f t h e e x t e n s i o n of
pseudopodial processes in Waldenstrom's macroglobulinemia (Xt5,800);
D. Central retention of platelet substances in thrombocytopathy A
(X4,300).

Modifications for scanning electron microscopy (SEM)
A recent modification of our standard method uses the
scanning electron microscope (7, 10-12) to display the
surface topography of adherent single platelets and
aggregates.

have been able to pinpoint the origin of functional platelet
faults and to establish a relationship between the observed
platelet response and the basic etiologic mechanism of
these disease processes.

Platelets are collected onto the surface of the Formvar
film, which is rinsed with Tyrode's solution as described
previously. Fixation is accomplished by exposing the adherent platelet population to cacodylate buffered 3% glutaraldehyde for 1 hour at room temperature. At this point,
two routes of final processing are possible. In one, the
preparation is rinsed in distilled water and the exterior
surface of the platelets is stabilized by a brief exposure to
Parducz's fixative (13) for 15 minutes at room temperature.
The doubly fixed sample is then rinsed once again with
distilled water and placed in 70% ethanol for 5 minutes.
Next, the preparation is withdrawn and allowed to air dry.
If air drying is not desirable, the platelets fixed with glutaraldehyde can be stabilized by critical point drying. In
the final step before SEM viewing, a thin layer of goldpalladium is deposited over the exterior of the preparation
by the sputtering technique.

When platelet populations from patients with untreated
pernicious anemia were studied, the dendritic type of
platelet had defective pseudopodia. They were few in
number, short, and had a blunted end (Fig. 4). Even after
appropriate treatment, this defect persisted, just as some
erythrocytes also do not revert to an entirely normal state
(14).
An altered ability to form pseudopodia was also detected in
two other diseases, idiopathic thrombocytopenic purpura
(ITP) and Waldenstrom's macroglobulinemia. In ITP, the
pseudopodial processes were abortive and malformed so
that they appeared as short, rather broad extensions with a
flattened end. The border of some ofthese platelets therefore presented a serrated, gear-like appearance (15). Itwas
suggested that the antiplatelet antibodies present had attached to small, distinct plateaus at affected sites. (Fig. 4).
These findings were similar to those produced when
known antierythrocytic antibodies were exposed to the
surface of sensitized erythrocytes. In Waldenstrom's

Applications of the Method
Clinical studies of selected disease states
By obtaining a pictorial TEM record ofthe activation state
of certain populations of platelets in several diseases, we

270

Riddle

macroglobulinemia, pseudopodial formation appeared to
be prevented (16) because the entire platelet surface was
coated nonspecifically with the macroglobulin (Fig. 4). In
view of more recent advances, it may be that this coating
prevented triggering substances from reaching specific receptor sites on the platelet surface.

We have also determined platelet reactivity in patientswith
classical rheumatoid arthritis. Increased platelet surface
activation was found in 8 of 25 women and 8 of 15 men or
40% of these patients (26). Although the level of platelet
response did not correlate with either the presence of
rheumatoid nodules or the titer of rheumatoid factor, it did
correspond with serum urate level above 5 mg%. In rheumatoid arthritis, platelets may also be activated by interactions between platelets and immune complexes, since
these antigen-antibody combinations are known to trigger
the platelet surface response.

A direction for determining the functional abnormality
associated with thrombocytopathy A was suggested when
platelet differential counts from these subjects consistently
exhibited a distinctive spread type with a well defined,
electron-dense central zone (Fig. 4). This finding implied
that essential substances were not being released from the
platelet during its surface activation sequence. When these
platelets were subjected to sonic oscillation or extracted
with distilled water, the hypothesis was substantiated because platelet factor 3 was released in normal amounts,
and the altered prothrombin consumption, a regular feature
ofthis disease state, was corrected (17,18).

Metabolic studies
Our basic method can be adapted to monitor alterations of
the platelet response by any substance that is water soluble.
Comparison of the results obtained from the differential
counts of the collected platelets in the absence and presence of such a substance demonstrates whether it exerts a
direct potentiating action or an inhibitory effect on the
surface response of the platelet population chosen for
study.

In more recent years, our modifed method has been used to
help determine the prethrombotic state and to evaluate an
ongoing thrombotic episode. When we evaluated the
platelet populations of patients with clinical myocardial
infarction during late stage convalescence (7,19), not only
was there increased surface response coincident with the
infarction, but a hyperactive platelet response persisted in
67% of these patients. These data suggest that if both
increased surface activation and increased aggregation
continue, the patient may be predisposed to future thrombotic episodes despite apparently satisfactory clinical recovery from the initial myocardial infarction.

To determine whether or not a metabolic product that
increases in response to a disease process will trigger
surface activation, platelet populations from asymptomatic
subjects should be used. On the other hand, to determine
the inhibitory capacity of drugs that might aid in treating
clinical disease states involving thrombosis, platelet populations from patients with an abnormally activated surface
response should be used.
As an example of the former, we combined varying concentrations of uric acid with normal platelet populations
from six asymptomatic subjects to determine if the hyperuricemia found in primary gout might serve as a triggering
mechanism for the increased platelet response associated
with over half of the gouty patients. As we increased the
concentration of urate, we observed a corresponding elevation in the percentage of spread types and platelet
aggregates (27). At levels of urate comparable to those seen
in primary gout patients, the platelet differential count of
the test system mimicked that found in the primary gout
patients who demonstrated an increased level of platelet
reactivity.

In another series of studies, the platelet response of patients
with varying degrees of cerebrovascular disease was determined. During an acute stroke phase, platelet populations
from 85% of the 31 patients tested were hyperreactive,
while increased platelet activity was noted in only 36% of
25 patients with chronic cerebrovascular disease (10,
20-22). Of 20 patients with an established diagnosis of
transient ischemic attacks, only 30% had platelet populations with increased surface activation (23).
Certain forms of arthritis, e.g., primary gout (24) and rheumatoid arthritis, also have clinically evident thrombotic
episodes as a part of the total disease process. To date, we
have evaluated platelet populations from 124 patients with
primary gout. More than half (55%) demonstrate primed
platelet populations so that their degree of surface activation and/or tendency to form aggregates is abnormally
increased (25). Our studies suggest that the episodes of
arterial thrombosis in gout may be related to the platelet
hyperactivity induced in these patients by the associated
hyperuricemia and possible deposition of urate crystals
within vessels.

Since blood levels of fibrinogen split products (FSP) and
biologic amines increase during minor trauma and in acute
thromboembolic disease, the effect of FSP (28-30), epinephrine, norepinephrine, and serotonin on the surface
response of platelet populations from asymptomatic subjects was evaluated (11). Serotonin and FSP significantly
increased their capacity for cohesion so that increased
numbers of platelet aggregates were present, while epinephrine, in addition to increasing aggregation, also accel-

271

Platelet Response by Electron Microscopy

erated hyalomeric spreading. The extent of the altered
platelet response was concentration dependent. These
studies provide indirect evidence that as the stressful process of thrombosis occurs, release of these biogenic amines
and products of fibrinolysis may prime the circulating
blood platelets so that they contribute further to the disease
process.

gout, we found that the degree of surface response of each
population was abnormally increased, that is, the percentage of spread types was consistently elevated and the
amount of aggregation was generally elevated (Figs. 5, 7).
Colchicine, phenylbutazone, and probenecid (Table I) did
not appear to block either the degree of hyalomeric spreading or the amount of aggregation appreciably (25). We
therefore considered these compounds to be noninhibitory.
Conversely, a l l o p u r i n o l (Fig. 6), o x y p u r i n o l , sulfinpyrazone, (anturan), halofenate, indomethacin (27), and
periactin were effective to varying degrees in either directly
blocking the amountof hyalomeric spreading, in reducing
the aggregability of the platelets, or in mediating both
(Table II). Consequently, we feel that this type of study is a
valuable guide in selecting drugs to be tested as potential
antithrombotic agents for subsequent clinical trials.

Studies with pharmaceutical agents
We have added a variety of therapeutic agents to platelet
populations from patients with primary gout to evaluate
their potential inhibitory action on an abnormally increased surface response. One of the concentrations represented a feasible blood level value for the drug as it is
administered in an ordinary clinical setting. Using platelet
populations from either three or six patients with primary

TABLE 1
Noninhibitory Agents

Colchicine

Phenylbutazone

Probenecid

. ••-'

o

%R-FD
%S
RAGG.
Normal

Fig. 5
Platelet population from a patient w i t h primary gout showing an increased n u m b e r of spread t y p e p l a t e l e t s and h y p e r a g g r e g a b i l i t y
(X4,700).

Drug Conc. ( u g / m l )
No Drug
0.05
*0.25
0.50

%R-I-D
12
49
5
33

%S
88
51
95
67

P.AGG
337
244
178
158

No Drug
10
*30
100

57
46
58
3

43
54
42
97

202
200
201
385

No Drug
50
•100

27
24
33

73
76
67

203
182
182

= percentage of round plus dendritic types counted
= percentage of the spread type counted
= platelet aggregates per 100 single platelets counted
range = R + D = 8 8 % ± 7 ; S = l 2% ± 7 ; P.AGG. = 6 8 ± 5 0

* = potentially attainable blood level during in vivo administration

Fig. 6
In the presence of allopurinol, the platelet surface response of triggered
platelets was inhibited in vitro so that dendritic type platelets and
aggregates predominated rather than spread types (X4,500).

Fig. 7
Platelet population from a patient w i t h primary gout before treatment.
Note dominant spread type platelet and large, numerous aggregates
(X4,500).
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When platelet populations from 8 patients were surveyed
24 hours after treatment with allopurinol, platelet reactivity
was reduced to within normal limits in 3 of the 8 (38%). In
all cases, the serum uric acid remained abnormally increased. If the results for the entire treatment series were
averaged, the state of platelet reactivity was reduced to
within normal limits, as demonstrated by the dominance of
dendritic types (Fig. 8) for 8 of 11 (73%) patients. The serum
uric acid level was reduced to within normal limits in only
4 of these 11 (36%). We observed the coexistence of a
normally reactive platelet population and an increased
serum uric acid level in 6 of the 11 patients (55%). These
data suggest that allopurinol exerts a rather immediate in
vivo inhibitory action on platelet surface activation (Fig. 9)
which parallels its in vitro antiplatelet action.

T A B L E II
Inhibitory Agents
Drug Gone, (ug/ml)

No Drug
Allopurinol

Oxypurinol

Sulfinpyrazone

Halofenate

Periactin

%R-I-D
%S
RAGG.
Normal

% S P.AGG.

12
*40
120

44
100
98
98

56
0
2
2

264
110
34
46

No Drug
14
28
98

47
63
82
91

53
37
18
9

104
81
65
50

No Drug
*12
40
120

78
98
96
81

22
2
4
19

170
174
147
104

No Drug

55
34
79
87

45
66
21
13

137
166
107
59

too
200
MOO

Indomethacin

%R + D

No Drug
3
*7
14

80
76
97
97

20
24
3
3

187
145
148
102

No Drug
*0.1
30
100

31
98
76
45

69
2
24
55

120
66
153
192

Discussion
Through the years, investigations on the structure, biochemistry, and clinical importance of blood platelets have
steadily increased. A variety of methods have been devised
to determine the adhesive and cohesive qualities of platelet
populations from both asymptomatic subjects and patient
groups representing various disease states. The most popular method to monitor platelet function in today's clinical
setting is the photometric test, or so-called platelet aggregometry (31, 32). Essentially, this method records photometrically the aggregation of platelets after a triggering
substance has been added to an isolated and selectively
concentrated population. Its advantages are that the platelet response to a wide variety of agents can be obtained at
different concentration levels and the character of the
response (reversible vs irreversible aggregation) can be
visualized. The disadvantages of aggregometry are that it is

= percentage of round plus dendritic types counted
= percentage of the spread lype counted
= platelet aggregates per 100 single platelets counted
range = R + D = 8 8 % ± 7 ; S = 1 2 % ± 7 ; RAGG. = 6 8 ± 5 0

* = potentially attainable blood level during in vivo administration

Clinical trials
Finally, we studied serial changes in the platelet surface
response when a therapeutic agent is administered to
patients with a defined disease process. We have
monitored the activation for platelet populations before
and duringthe daily administration of allopurinol (300-600
mgs) in 11 patients with primary gout. Platelet differential
counts were performed in six before treatment and according to the following post-treatment schedule: 24 hours, 48
hours, 1, 2, 4, 6, 8, 12,16, 20, and 24 weeks. The sampling
schedule for the other five patients was less structured, and
the period of treatment varied from as short as 1 week to as
long as 8 weeks.
Surface activation was increased to abnormal limits with a
predominance of the spread type and/or an increased
number of aggregates (Fig. 7) in each of these 11 patients
before treatment with allopurinol. Initially, in 9 of 11, the
serum uric acid level was greater than 5.5 mg% (82%).

Fig. 8
Allopurinol in vivo inhibited platelet surface response so that normal
appearing dendritic types dominated (X5,600).
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subjected to only minimal manipulation after blood is
withdrawn; 2) steps in the procedure are simple and can be
accomplished in a short time; 3) the activating surface, a
Formvar film, has a uniform composition and reproducible
characteristics; and 4) a pictorial record of surface activation and aggregation is available so that structural characteristics of the platelet population can be investigated. The
major disadvantages of this technique are: 1) a transmission
electron microscope is required to perform the platelet
differential count adequately; and 2) the population of
platelets evaluated may not be wholly representative of the
total platelet population, if for some reason a particular
functional state is selectively collected on the surface ofthe
Formvar film during incubation.

IN VIVO ALLOPURINOL (W.B.)
URIC ACID (mg%)

10
5
0
200

PLATELET AGGREGATES

1 50
100

50
0
100

The versatility of our technique is broad. Because results
are consistent, the platelet response of a normal subject,
patients w i t h various disease states, or of different
therapeutic regimens can be evaluated over a long time
through serial sampling. In addition, the capacity of a
substance to either trigger or inhibit a platelet's surface
response can be detected, depending upon whether a
normal ly reactive platelet population or one with increased
reactivity is used to monitor the effect.

7o SPREAD TYPE
PLATELETS

0

1

2

14

30 6 0

Any method, either established or prospective, that is
designed to evaluate platelet response should answer the
following questions: 1) Can this test system reliably select
persons within the general population who are at a high
risk for thrombosis? 2) Is it useful in predicting if an
established thrombus will extend? 3) Does a defined biochemical alteration constitute a risk factor for thrombosis?
4) What drugs are effective antiplatelet agents both in vitro
and in vivo?

120

DAYS POST-ALLOPURINOL
Fig. 9
Abnormal pretreatment parameters of primary gout (hyperuricemia and
hyperresponsive platelets) normalized by allopurinol therapy.

time consuming, and the platelet population being studied
undergoes extensive handling, such as centrifugation and
adjustment of the count per mm^, before its functional
capacity is evaluated.

Our method appears to be suitable for assessing the degree
of surface response for any platelet population, for determining the in vitro action of a variety of substances on the
platelet response, and for measuring the antiplatelet capacity of established as well as experimental therapeutic
agents.

Both the technique used by Breddin (33) and our procedure
(7) provide a more direct record of platelet populations as
they participate in surface activation and aggregation. The
advantages of our technique are: 1) platelet populations are
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